X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3610) 3610
Publication (187) 187
Book Review (19) 19
Dissertation (4) 4
Magazine Article (4) 4
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3145) 3145
male (2303) 2303
2-pyridinylmethylsulfinylbenzimidazoles (2198) 2198
omeprazole - analogs & derivatives (1967) 1967
female (1966) 1966
lansoprazole (1966) 1966
middle aged (1608) 1608
adult (1576) 1576
proton pump inhibitors (1488) 1488
gastroenterology & hepatology (1242) 1242
omeprazole (1164) 1164
pharmacology & pharmacy (1083) 1083
aged (1052) 1052
anti-ulcer agents - therapeutic use (1017) 1017
omeprazole - therapeutic use (963) 963
helicobacter infections - drug therapy (882) 882
index medicus (858) 858
treatment outcome (807) 807
rabeprazole (805) 805
helicobacter pylori (711) 711
drug therapy, combination (682) 682
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (646) 646
anti-ulcer agents - administration & dosage (625) 625
pantoprazole (616) 616
omeprazole - administration & dosage (592) 592
gastroesophageal reflux - drug therapy (581) 581
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (493) 493
benzimidazoles - therapeutic use (465) 465
proton pump inhibitor (443) 443
animals (441) 441
omeprazole - pharmacology (432) 432
double-blind method (423) 423
adolescent (383) 383
prospective studies (381) 381
helicobacter pylori - drug effects (370) 370
amoxicillin - therapeutic use (369) 369
anti-ulcer agents - pharmacology (361) 361
anti-bacterial agents - therapeutic use (357) 357
clarithromycin - therapeutic use (336) 336
infection (335) 335
anti-ulcer agents - adverse effects (332) 332
time factors (329) 329
dose-response relationship, drug (318) 318
hydrogen-ion concentration (317) 317
pharmacokinetics (315) 315
benzimidazoles - administration & dosage (314) 314
amoxicillin - administration & dosage (310) 310
proton pump inhibitors - therapeutic use (306) 306
aged, 80 and over (303) 303
omeprazole - adverse effects (300) 300
drug administration schedule (299) 299
benzimidazoles - pharmacology (298) 298
clarithromycin - administration & dosage (287) 287
2-pyridinylmethylsulfinylbenzimidazoles - adverse effects (276) 276
enzyme inhibitors - therapeutic use (272) 272
cross-over studies (267) 267
sulfoxides - therapeutic use (267) 267
anti-bacterial agents - administration & dosage (266) 266
therapy (266) 266
rats (260) 260
administration, oral (251) 251
proton pump inhibitors - administration & dosage (250) 250
2-pyridinylmethylsulfinylbenzimidazoles - pharmacology (249) 249
eradication (245) 245
cytochrome p-450 cyp2c19 (242) 242
duodenal ulcer - drug therapy (241) 241
drug interactions (236) 236
amoxicillin (234) 234
peptic ulcer - drug therapy (234) 234
clarithromycin (229) 229
gastroesophageal reflux (221) 221
medicine & public health (217) 217
omeprazole - pharmacokinetics (212) 212
ranitidine (212) 212
duodenal-ulcer (210) 210
efficacy (208) 208
helicobacter infections - complications (205) 205
management (202) 202
young adult (198) 198
gastroesophageal-reflux disease (197) 197
gastroesophageal reflux disease (194) 194
triple therapy (194) 194
enzyme inhibitors - pharmacology (193) 193
benzimidazoles - adverse effects (192) 192
stomach ulcer - drug therapy (191) 191
follow-up studies (190) 190
helicobacter infections - microbiology (189) 189
sulfoxides - administration & dosage (187) 187
esophagitis, peptic - drug therapy (186) 186
anti-ulcer agents - pharmacokinetics (185) 185
medicine, general & internal (185) 185
double-blind (182) 182
esophagitis (181) 181
gastric acid - secretion (181) 181
helicobacter pylori - isolation & purification (179) 179
enzyme inhibitors - administration & dosage (177) 177
genotype (174) 174
gastric acid - metabolism (171) 171
aryl hydrocarbon hydroxylases - genetics (168) 168
gastric mucosa - drug effects (166) 166
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3285) 3285
Japanese (193) 193
German (69) 69
Russian (63) 63
Spanish (43) 43
Chinese (35) 35
French (33) 33
Korean (12) 12
Ukrainian (7) 7
Italian (6) 6
Hungarian (5) 5
Polish (4) 4
Danish (3) 3
Dutch (3) 3
Norwegian (3) 3
Czech (2) 2
Portuguese (2) 2
Turkish (2) 2
Croatian (1) 1
Finnish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2008, Volume 48, Issue 4, pp. 475 - 484
Journal Article
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 9/2018, Volume 74, Issue 9, pp. 1149 - 1157
Ilaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori.... 
Clarithromycin | Biomedicine | Amoxicillin | Drug interaction | Ilaprazole | Pharmacology/Toxicology | Pharmacokinetics | Proton pump inhibitor | DUODENAL-ULCER | OMEPRAZOLE | PLASMA | DOUBLE-BLIND | TRIPLE THERAPY | PHARMACOLOGY & PHARMACY | ERADICATION | CURE | HEALTHY-VOLUNTEERS | HELICOBACTER-PYLORI | Anti-Bacterial Agents - blood | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Healthy Volunteers | Clarithromycin - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - pharmacokinetics | Patient Safety | Clarithromycin - administration & dosage | Adult | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Proton Pump Inhibitors - blood | Drug Therapy, Combination | Republic of Korea | Proton Pump Inhibitors - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Risk Assessment | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Amoxicillin - blood | Amoxicillin - pharmacokinetics | Cross-Over Studies | Proton Pump Inhibitors - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Amoxicillin - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | 2-Pyridinylmethylsulfinylbenzimidazoles - blood | Helicobacter Infections - microbiology | Complications and side effects | Dosage and administration | Safety and security measures | Drug interactions | Confidence intervals | Therapy | Randomization | Statistical analysis | Pharmacology | Safety | Pharmacokinetics and Disposition
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2018, Volume 74, Issue 3, pp. 257 - 265
The objective of this study was to evaluate the safety, pharmacokinetics, and pharmacodynamics of S-(−)-pantoprazole (PPZ) sodium injections following single... 
Biomedicine | Pantoprazole | Gastric acid inhibition | S-(−)-pantoprazole sodium injection | Pharmacodynamic | Safety | Pharmacology/Toxicology | Pharmacokinetic | STEREOSELECTIVE PHARMACOKINETICS | PANTOPRAZOLE ENANTIOMERS | RATS | PROTON PUMP INHIBITORS | PHARMACOLOGY & PHARMACY | S-(-)-pantoprazole sodium injection | Proton Pump Inhibitors - pharmacology | Injections, Intravenous | Area Under Curve | Stereoisomerism | Humans | Half-Life | Male | Metabolic Clearance Rate | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Gastric Acid - secretion | Proton Pump Inhibitors - administration & dosage | China | Gastric Acidity Determination | Gastric Mucosa - drug effects | Drug Compounding | Adult | Anti-Ulcer Agents - pharmacology | Female | Proton Pump Inhibitors - adverse effects | Reproducibility of Results | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Anti-Ulcer Agents - adverse effects | Anti-Ulcer Agents - administration & dosage | Monitoring, Ambulatory | Proton Pump Inhibitors - pharmacokinetics | Gastric Mucosa - secretion | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Yuan (China) | Metabolic rate | Pharmacodynamics | Intravenous administration | Statistical analysis | Pharmacology | pH effects | Dosage | Laboratory tests | Sodium | Hydrogen ions | Acids | In vivo methods and tests | Pharmacokinetics | Asians
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 4, pp. 1314 - 1322.e5
Background & Aims Proton pump inhibitors (PPIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used classes of drugs, with the... 
Gastroenterology and Hepatology | Ulcer | Microflora | Bleeding | Acid Secretion | ULCERS | NONSTEROIDAL ANTIINFLAMMATORY DRUG | PERMEABILITY | RATS | INDOMETHACIN | LEUKOCYTE ADHERENCE | INDUCED GASTRIC DAMAGE | PATHOGENESIS | NITRIC-OXIDE | BACTERIAL OVERGROWTH | GASTROENTEROLOGY & HEPATOLOGY | Jejunum - pathology | Rats, Wistar | Colon - drug effects | Hematocrit | Peptic Ulcer - prevention & control | Male | Omeprazole - toxicity | Bifidobacterium - isolation & purification | Bifidobacterium - growth & development | Actinobacteria - drug effects | Jejunum - drug effects | Drug Interactions | Peptic Ulcer - microbiology | Time Factors | Actinobacteria - genetics | Actinobacteria - isolation & purification | Disease Models, Animal | Bifidobacterium - genetics | Jejunum - microbiology | Rats | Celecoxib | Probiotics - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Proton Pump Inhibitors - toxicity | Anti-Inflammatory Agents, Non-Steroidal - toxicity | Peptic Ulcer - pathology | Denaturing Gradient Gel Electrophoresis | 2-Pyridinylmethylsulfinylbenzimidazoles - toxicity | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Bifidobacterium - drug effects | Animals | Gastrointestinal Hemorrhage - microbiology | Actinobacteria - growth & development | Pyrazoles - toxicity | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Naproxen - toxicity | Sulfonamides - toxicity | Colon - microbiology | Peptic Ulcer - chemically induced | Gastrointestinal Hemorrhage - pathology | Lansoprazole | Proton pump inhibitors | Messenger RNA | Nonsteroidal anti-inflammatory drugs
Journal Article
Journal Article